Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.

ABSTRACT: CSF biomarkers, including total-tau, neurofilament light chain (NfL) and amyloid-β, are increasingly being used to define and stage Alzheimer's disease. These biomarkers can be measured more quickly and less invasively in plasma and may provide important information for early diagnosis of Alzheimer's disease. We used stored plasma samples and clinical data obtained from 4444 non-demented participants in the Rotterdam study at baseline (between 2002 and 2005) and during follow-up until January 2016. Plasma concentrations of total-tau, NfL, amyloid-β40 and amyloid-β42 were measured using the Simoa NF-light® and N3PA assays. Associations between biomarker plasma levels and incident all-cause and Alzheimer's disease dementia during follow-up were assessed using Cox proportional-hazard regressi

SUBMITTER: de Wolf F 

PROVIDER: S-EPMC7174054 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature